Table 6.

Hazard of Outcomes in Matched Cohorts of Men and Women

	Women		Men
	Adjusted Hazard Ratio (95% Confidence Interval)	P Value	Adjusted Hazard Ratio (95% Confidence Interval)	P Value
Myocardial infarction
Rivaroxaban vs warfarin	0.94 (0.65–1.37)	0.76	0.64 (0.43–0.97)	0.03
Dabigatran vs warfarin	0.96 (0.67–1.39)	0.84	0.96 (0.66–1.39)	0.83
Rivaroxaban vs dabigatran	0.98 (0.67–1.43)	0.92	0.67 (0.44–1.01)	0.06
Heart failure
Rivaroxaban vs warfarin	0.64 (0.56–0.74)	<0.001	0.75 (0.63–0.89)	0.001
Dabigatran vs warfarin	0.73 (0.63–0.83)	<0.001	0.81 (0.69–0.96)	0.02
Rivaroxaban vs dabigatran	0.88 (0.77–1.02)	0.09	0.92 (0.77–1.10)	0.39
All‐cause mortality
Rivaroxaban vs warfarin	0.76 (0.63–0.91)	0.004	0.66 (0.53–0.81)	<0.001
Dabigatran vs warfarin	0.77 (0.64–0.93)	0.006	0.75 (0.61–0.93)	0.008
Rivaroxaban vs dabigatran	0.98 (0.81–1.20)	0.86	0.81 (0.70–1.10)	0.25